Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

Phase 2

Recruiting

Conditions: Acute Leukemia
Acute Lymphoblastic Leukemia
Anaplastic Large Cell Lymphoma
Acute Myeloid Leukemia
Adult Diffuse Large Cell Lymphoma
Lymphoplasmacytic Lymphoma
Mantle Cell Lymphoma
Mixed Phenotype Acute Leukemia
Myelodysplastic Syndrome
Prolymphocytic Leukemia

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Cyclophosphamide
Drug: Cyclosporine
Biological: Filgrastim
Drug: Fludarabine
Drug: Mycophenolate Mofetil
Drug: Mycophenolate Sodium
Radiation: Total-Body Irradiation
Drug: Treosulfan
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Procedure: Echocardiography
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Positron Emission Tomography

First Posted Date: 2019-12-12

Last Posted Date: 2024-08-28

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 60

Registration Number: NCT04195633

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas(DIPG) & Spinal Diffuse Midline Glioma(DMG)

Phase 1

Recruiting

Conditions: Glioma of Brainstem
Glioma of Spinal Cord

Interventions: Drug: GD2 CAR T cells
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2019-12-12

Last Posted Date: 2024-10-17

Lead Sponsor: Crystal Mackall, MD

Target Recruit Count: 54

Registration Number: NCT04196413

Locations: 🇺🇸
Lucile Packard Children's Hospital (LPCH), Stanford, California, United States

Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies

Phase 2

Active, not recruiting

Conditions: Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Biphenotypic Acute Leukemia
Undifferentiated Leukemia
Prolymphocytic Leukemia
Myelodysplastic Syndromes
Lymphoplasmacytic Lymphoma
Chronic Myelogenous Leukemia
Myeloproliferative Neoplasm
Relapsed Large Cell Lymphoma

Interventions: Drug: Fludarabine
Drug: Melphalan
Radiation: Total Body Irradiation

First Posted Date: 2019-12-09

Last Posted Date: 2024-12-13

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 37

Registration Number: NCT04191187

Locations: 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States

Study of alloCART-19 Cell Therapy in Pediatric Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Early Phase 1

Active, not recruiting

Conditions: ALL, Childhood B-Cell

Interventions: Genetic: alloCART-19
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2019-11-22

Last Posted Date: 2024-03-15

Lead Sponsor: Children's Hospital of Fudan University

Target Recruit Count: 6

Registration Number: NCT04173988

Locations: 🇨🇳
Children's Hospital of Fudan University, Shanghai, Minhang, China

A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed/Refractory Multiple Myeloma

Phase 1

Terminated

Conditions: Relapsed/Refractory Multiple Myeloma

Interventions: Genetic: PBCAR269A
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Nirogacestat

First Posted Date: 2019-11-21

Last Posted Date: 2023-09-21

Lead Sponsor: Precision BioSciences, Inc.

Target Recruit Count: 48

Registration Number: NCT04171843

Locations: 🇺🇸
MD Anderson, Houston, Texas, United States
🇺🇸
Columbia University Irving Medical Center, New York, New York, United States
🇺🇸
University of California San Francisco, San Francisco, California, United States

and more 2 locations

Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02

Phase 1

Recruiting

Conditions: Acute Myeloid Leukemia
Myelodysplastic Syndrome

Interventions: Biological: CYAD-02
Drug: ENDOXAN
Drug: Fludara

First Posted Date: 2019-11-19

Last Posted Date: 2020-06-09

Lead Sponsor: Celyad Oncology SA

Target Recruit Count: 27

Registration Number: NCT04167696

Locations: 🇺🇸
University of Kansas Cancer Center, Fairway, Kansas, United States
🇧🇪
Uz Leuven, Leuven, Belgium
🇺🇸
Mayo Clinic Cancer Center, Jacksonville, Florida, United States

and more 2 locations

Study of Brexucabtagene Autoleucel (KTE-X19) for the Treatment of Individuals With Relapsed/Refractory B-Cell Malignancies

Conditions: Relapse/Refractory Mantle Cell Lymphoma

First Posted Date: 2019-11-14

Last Posted Date: 2021-10-14

Lead Sponsor: Kite, A Gilead Company

Registration Number: NCT04162756

Locations: 🇺🇸
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸
Stanford Cancer Institute, Stanford, California, United States

and more 6 locations

T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma

Phase 1

Terminated

Conditions: Lymphoma, Non-hodgkins
Lymphoma, B-Cell
B-Cell Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia

Interventions: Biological: Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptors (CAR) and Anti-cluster of differentiation 20 (CD20)-CAR T cells
Drug: Cyclophosphamide
Drug: Fludarabine